Health experts in Australia believe that around 12% of Australians will experience PTSD (post-traumatic stress disorder) at some point in their lives, and about 1.5% of the population, i.e. almost 390,000 people, currently have a PTSD diagnosis. Certain groups, like those in the defence force, military veterans, first responders, and some minority communities, are more
Read MoreIn February 2023, Australia became the first country to accept psychedelics, i.e. hallucinogenic drugs, as medicine. It approved the use of MDMA and psilocybin, typically known as mushrooms and ecstasy, for psychiatric help. Medical cannabis and psychedelics manufacturer Incannex Healthcare (ASX: IHL) wasted no time and announced the launch of the first psychedelic-assisted psychotherapy clinic.
Read MoreIncannex Healthcare (ASX: IHL) has reported interim data from its Phase 2 clinical trials to treat anxiety through the use of psychedelics. Upon completion of the trials, the Company will seek to progress this new therapy and offer renewed hope for individuals seeking non-pharmacological solutions to treat mental health. Psilocybin-assisted psychotherapy has emerged as the
Read MoreUnsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte* People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial
Read MoreThroughout the 1950s, psychotherapy was a form of treatment for mental disorders from limited research but with the world having undertaken medical breakthroughs since, pharmaceuticals company Incannex Healthcare (ASX: IHL) is re-visiting the use of psilocybin as a treatment for anxiety through clinical trials in partnership with Monash University. Psilocybin is better known as magic
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.